Overview

MAD Study of IA-14069

Status:
Not yet recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple ascending oral doses of IA-14069 in healthy subjects and in patients with RA on stable dosese of MTX, with preliminary assessment of efficacy in RA patients.
Phase:
Phase 1
Details
Lead Sponsor:
ILAb Co., Ltd.
Treatments:
Methotrexate